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Abstract  
Introduction: Outpatient parenteral antimicrobial therapy (OPAT) has gained popularity 
since its first description in 1974. At Community Health Network (CHN), the OPAT 
clinic was developed three years ago by an ambulatory care clinical pharmacist and 
includes pharmacist driven monitoring for all patients receiving OPAT. The pharmacist 
ensures labs are drawn weekly to assess for renal or hepatic function changes, medication 
levels are drawn and adjusted as needed, and repeat labs and levels are ordered to 
continue assessing therapy. There have not been any studies to date to investigate CHN’s 
OPAT program both demographically and clinically. 
Objectives: The primary objective of this study was to qualitatively determine the 
number of patients, types of infections, source organism, antibiotics utilized, duration of 
therapy, adverse effects, and number and types of interventions made to therapy by the 
OPAT clinical pharmacist. 
Methods: This study was conducted via retrospective chart analysis and included both 
demographic and clinical information such as infection type, source organism(s), 
antibiotic, duration of therapy, adverse effects, and successful completion of OPAT 
regimen. Information regarding number and type of pharmacist intervention were also 
recorded. Patients who received OPAT from January 2017 to January 2018 were included 
in the study.  
Results: 226 patients were included in the study. Over ten different types of infections 
were identified with osteomyelitis being most common (n=65). The majority of 
infections were attributed to Staphylococcus aureus both methicillin sensitive and 
methicillin resistant organisms with another large portion deemed culture negative. 
Antibiotics used in the OPAT program primarily consisted of vancomycin (n=67), 
ceftriaxone (n=60), and cefazolin (n=52). The mean total duration of treatment was 42.7 
days and a mean of 33.45 of those occurred via OPAT once the patient was discharged. 
The pharmacist made a total of 138 interventions equaling about 0.6 interventions per 
patient. 93.4% of patients included successfully completed the OPAT program.  
Conclusion: CHN’s OPAT program involved a wide variety of patients with diverse 
infections and antibiotic therapy. This study helped to successfully determine the 
demographic and clinical information from January 2017 to January 2018. High rates of 
success in CHN’s OPAT program provides support for continued use in the future with 
pharmacist involvement. 
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Introduction 
 Since outpatient parenteral antimicrobial therapy (OPAT) was first described by 
Rucker and Harrison in 1974, its usage has become increasingly common in infectious 
disease practices.1 Because of the increase in healthcare costs combined with improved 
technology, delivering intravenous (IV) antibiotics to patients outpatient via OPAT 
programs has helped to cut down on inpatient medical costs as well as improve patient 
satisfaction in some cases.2,3 
Today, OPAT is used for skin and soft tissue infections, osteomyelitis, 
bacteremia, meningitis, and pyelonephritis among others.4 Some of the most common 
antibiotics used for OPAT include ceftriaxone, vancomycin, penicillins, and 
meropenem.4 Not all infections requiring IV therapy qualify for OPAT. Considerations 
for OPAT often include appropriateness of IV therapy, clinical stability, ability for 
follow-up, previous antibiotic use, medical history including substance abuse, and 
infection type.5 
Many studies have evaluated OPAT’s efficacy and safety as an alternative to 
inpatient IV antibiotics.6 Decreased costs and improved recovery both physically and 
psychologically make OPAT a preferable option for many patients.2,3,6 Previous analysis 
of OPAT programs utilizing pharmacists have shown improved patient safety, increased 
treatment efficacy, and resulted in a reduction in healthcare costs.7 A study of 
Staphylococcus aureus skin and soft tissue infections from 2001-2009 determined that 
the average cost of hospitalization and treatment was $11,622 inpatient.8 Eisenberg and 
colleagues specifically analyzed the cost savings associated with treating osteomyelitis 
outpatient versus inpatient and found savings ranging from $510 to $22,232 depending 
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on hospital cost data.9 Apart from a cost-savings perspective, OPAT has been shown to 
be effective in treating common infections with the added benefit of being able to receive 
treatment outside of the hospital with comparable treatment efficacy and improved 
patient satisfaction.10,11 
 At Community Health Network (CHN), OPAT is coordinated by an infectious 
disease doctor and an ambulatory care clinical pharmacy specialist. The OPAT clinic was 
developed by the pharmacist three years ago when she implemented a pharmacist driven 
monitoring system for all patients receiving OPAT. Before her arrival, outpatient 
infusions were not monitored routinely and ordered labs were not assessed until beyond 
the ideal timeframe. Today, the pharmacist helps to coordinate all patients being 
discharged from the CHN system on OPAT by reviewing documentation including 
diagnosis, current therapy, and duration of therapy.  In patients who meet the appropriate 
criteria, the pharmacist ensures labs are drawn weekly to assess for any changes in renal 
or hepatic function, medication levels are drawn when appropriate, medications are 
adjusted as needed, and repeat labs and levels are ordered to continue improving therapy. 
Apart from monitoring labs and medication levels, the pharmacist also monitors for 
adverse effects of therapy and communicates with physicians to determine the need for 
therapy changes.  
 Since the OPAT program began at CHN, there has been no formal evaluation to 
determine the demographics or characteristics of this program specifically. There have 
been previous studies done at other institutions to help qualitatively analyze specifics of 
OPAT programs including type of infection, antibiotic, duration of therapy, and adverse 
effects.6,11 Because the OPAT program at CHN is relatively new and managed primarily 
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by a pharmacist, there is great value in gathering more information about the program. 
Knowledge about the number of interventions and the scope of use in CHN is needed to 
help further the development of the OPAT program and improve its utilization. 
 The primary objective of this study was to qualitatively determine the number of 
patients, types of infections, organism source, antibiotics utilized, duration of therapy, 
adverse effects identified, and number and types of interventions made to drug therapy 
regimens by the clinical pharmacist in the OPAT clinic at CHN. Secondary objectives 
were to determine successfulness of OPAT therapy by assessing clinical outcomes at the 
completion of therapy.  
Methods 
This study was conducted retrospectively utilizing data obtained from CHN’s 
electronic medical record (EMR), EPIC, from January 2017 to January 2018 and was 
IRB approved through both Butler University and CHN. Basic demographic and clinical 
data information was extracted from the EMR including age, sex, ethnicity, and type of 
insurance. Demographic endpoints were defined as the following: age in number of years, 
sex (male or female), ethnicity (white, black, Asian, Hispanic/Latino, other), and type of 
insurance (Medicaid, Medicare, commercial, other). 
Clinical data information collected included infection diagnosis, source 
organism(s), antibiotic selection, duration of therapy, occurrence of an adverse effect 
causing need for therapy change, completion of a successful OPAT regimen resulting in 
removal of the catheter and discontinuation of antibiotics, and number and type of 
pharmacist interventions made to therapy. Infection diagnosis was categorized as 
bacteremia, skin and soft tissue infections, osteomyelitis, intraabdominal, meningitis, 
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urinary tract infection/pyelonephritis, pneumonia, endocarditis, and other. Source 
organisms were categorized as methicillin sensitive Staphylococcus aureus (MSSA), 
methicillin resistant Staphylococcus aureus (MRSA), Streptococcus pneumonia, 
Pseudomonas spp., Escherichia coli, atypical organisms, anaerobic organisms, Group B 
Streptococcus, Enterococcus spp., culture negative, and other. Infections caused by 
multiple organisms included all causative organisms during data collection according to 
the mentioned categories. Antibiotics selected were defined using broad classes including 
penicillins, 1st, 2nd, 3rd, and 4th generation cephalosporins, carbapenems, macrolides, and 
other. It also accounted for specific agents including piperacillin/tazobactam, 
vancomycin, and ampicillin/sulbactam. If multiple antibiotics were used, they were all 
recorded as endpoints during data collection. Duration of therapy was defined as the total 
number of days receiving IV antibiotics and a separate category including number of 
days receiving IV antibiotics inpatient in case the patient had to be admitted during initial 
therapy. Outpatient days of therapy were extrapolated from the total duration and 
inpatient duration. Occurrence of an adverse effect requiring therapy change and 
successful completion signified via catheter removal were defined as yes or no. Finally, 
interventions made by the pharmacist were categorized as dose change, frequency 
change, antibiotic change, lab follow-up, level evaluation without dose adjustment, level 
evaluation with dose adjustment, and other. The pharmacist recorded her interventions in 
both her tracking sheet as well as with communication documented in the EMR. The 
secondary outcome of successful completion of the OPAT program was defined as 
discontinuation of IV antibiotics and removal of the patients’ peripherally inserted central 
catheter (PICC) line. 
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The patient population assessed consisted of any patients from January 2017 to 
January 2018 who qualified and began an OPAT regimen at CHN. All patients who 
began an OPAT regimen and received at least one dose were included in the study. 
Patients who do not receive at least one dose of their OPAT regimen were excluded from 
the study, as well as patients whose therapy was not monitored by the pharmacist were 
excluded. In addition, patients were excluded from the study if they are <18 years of age, 
>89 years of age, incarcerated, or pregnant.  
This study utilized descriptive analysis of patient demographics, types of 
infections, chosen antibiotics, adverse effects, and types of interventions by the 
pharmacist. Duration of therapy, number of interventions employed, and number of 
adverse effects were analyzed using qualitative analysis.  
Results 
Patient characteristics  
From January 2017 to January 2018, 284 patients were enrolled in CHN’s OPAT 
program. A total of 58 patients were excluded for a variety of reasons (Figure 1) and 226 
patients were included in analysis. Among those, 125 (55.3%) were male and 101 
(44.7%) were female. The majority of patients identified as Caucasian whereas there 
were no patients who identified as Asian or Hispanic. The average age of patients 
included in the study was 59 years old however, there was a wide range of ages of the 
patients who were included in the study. At the time of data collection, the majority of 
patients had Medicare coverage with commercial insurance and Medicaid following 
respectively. Full demographic details are described in Table 1.  
Primary Outcome 
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As previously mentioned the total number of patients enrolled in CHN’s OPAT 
program during the study time period was 284 patients. However, only 226 met inclusion 
criteria for this study. There were over ten different types of infections that were treated 
via CHN’s OPAT program within the study period. Osteomyelitis (n=65), prosthetic 
infections such as artificial hips and knees (n=33), endocarditis (n=15), and skin and soft 
tissue infections (n=15) were the most common amongst this patient population (Table 
2). Many of the infections were attributable to Staphylococcus aureus both methicillin 
sensitive and methicillin resistant strains. However, there was also a large portion of 
infections in which the source organism could not be identified and was deemed to be 
culture negative (Table 3). While the majority of infections fell within the predefined 
groups, there were several less common source organisms such as Serratia spp., 
Blastomycosis and Histoplasmosis (Table 3).  
The antibiotics used in the OPAT program primarily consisted of vancomycin and 
different generations of cephalosporins such as cefazolin and ceftriaxone. Carbapenems 
were also used frequently to treat patients in the OPAT program. Table 4 depicts the vast 
array of antibiotics that were used during treatment.  
Patients were treated with intravenous antibiotics for a mean of 42.7 days with 9.25 days 
of the total treatment occurring while the patient was in the hospital. Therefore, 33.45 
days of treatment occurred through OPAT where the patient was not in the hospital.  
Of the 226 patients analyzed in the study, only 26 (11.5%) patients experienced 
an adverse effect against their antibiotic therapy. Unfortunately, the specific adverse 
effect experienced was not recorded so a conclusion attributing adverse effects to certain 
antibiotic regimens or patients was not possible.  
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A total of 138 interventions were made in patients included in the study, resulting 
in an average of 0.6 interventions per patient. The number of interventions per patient 
ranged from zero to eight. Of the interventions made, 69 of them were level evaluations 
as part of therapeutic drug monitoring. Further classifications of interventions can be 
found in Table 5.  
Secondary outcome 
 Overall, 211 patients successfully completed the OPAT program, whereas 15 did 
not. Patients were unsuccessful at completing OPAT for a variety of reasons including 
completion of therapy with oral antibiotics before the infection resolved, and readmission 
causing IV antibiotics to be completed inpatient. This study demonstrated that 93.4% of 
the patients included in the study successfully completed their OPAT regimen and the 
infection resolved.  
Discussion 
 Patients who were enrolled in CHN’s OPAT program had a broad scope of 
demographics, a wide range of infections and source organisms, and received antibiotics 
from a variety of drug classes. The most common infections occurring in this patient 
population were not surprising. It is well known that osteomyelitis requires extended 
duration IV antibiotics which makes it a well-suited infection for treatment with OPAT. 
In addition, prosthetic infections are similar in duration of therapy. However, the number 
of hip and knee replacement infections was higher than anticipated. Interestingly, the 
infections generally occurred further down the road from the patient’s surgery. The few 
unique infection types such as meningitis, Lyme disease, and disseminated blastomycosis 
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were interesting examples of how OPAT therapy can be used for less traditional 
infections more commonly in the future.  
 The majority of antibiotics utilized in OPAT included ceftriaxone, vancomycin, 
and cefazolin. Because of their spectrum of activity including MSSA and MRSA, the 
most common source organisms, as well as their frequency of administration, these 
antibiotics made clinical and logistical sense for OPAT patients. Interestingly, 
daptomycin was used more often than expected. Typically, daptomycin is reserved for 
patients with vancomycin resistant enterococcus or vancomycin allergies. However, 
several patients experienced adverse effects to daptomycin or had declining kidney 
function making daptomycin a more suitable choice outpatient over vancomycin. Finally, 
a few less common anti-infectives such as colistin, amphotericin, tigecycline, and 
ceftazidime were used during OPAT. This could be support that more severe and/or 
resistant infections could be treated outpatient with appropriate follow-up.  
 A large proponent of OPAT is the ability for patients to receive IV antibiotics in 
their own homes or outside of the hospital rather than having to remain inpatient for 
extended durations. Doing so helps to theoretically decrease costs and improve patient 
satisfaction. In this study, the average length of time patients received antibiotics 
inpatient was 9.25 days. The mean total duration of therapy was 42.75 days. As a result, 
patients were treated outpatient with IV antibiotics for a mean of 33.5 days. This is 
consistent with the duration of 34 days found in the study by Chung and colleagues.5 
Therefore, patients were able to receive antibiotics outside of the hospital for a clinically 
significant amount of time. In addition, the success of OPAT therapy remained despite 
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nearly five weeks of outpatient antibiotics which otherwise would have been time spent 
in the hospital. 
 The success of therapy and decreased length of inpatient stay could only be made 
possible with continued outpatient monitoring of labs and drug levels. Because of this, 
interventions made by the pharmacist are important data points. Unfortunately, the 
retrospective nature of the study limited data collection of the pharmacist’s interventions 
to only those recorded in the tracking sheet or documented in the EMR. The pharmacist 
participates in monitoring of all lab results for patients such as basic metabolic panels 
(BMP) and complete blood counts (CBC) which occur periodically during treatment. She 
is also responsible for monitoring and following up on drug levels for antibiotics such as 
vancomycin or aminoglycosides. By understanding the day-to-day monitoring of labs and 
drug levels she does for the OPAT patients, it is believed that the number of interventions 
found in this study is an under representative of the work she does. When reviewing lab 
results, if the labs are normal or require no change in therapy that review is not 
documented in her tracking sheet nor in the EMR. Only if the labs are abnormal and 
require a change in therapy is that intervention documented. However, one could argue 
that reviewing all lab results for patients whether normal or abnormal is an intervention 
because the pharmacist is using her clinical knowledge to assess the patients’ therapy. If 
all lab reviews were documented in the EMR or tracking sheet, it would most likely 
display that the pharmacist is involved with each patient’s treatment regimen and 
monitoring plan.  
Another limitation of this study was that extrapolation of the results may not 
correlate to other OPAT programs in the area. In addition, by only analyzing patients 
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within 1 year, it is possible that more rare infections or antibiotic usage could have been 
missed in data collection.  
Conclusion 
With the expanse of home healthcare and increasing availability of home 
infusions, OPAT is becoming more common in patients who require antibiotics for an 
extended duration. This study helped to qualify the work that has been done in CHN’s 
OPAT program over the past year and will hopefully bring more knowledge and attention 
to the program’s scope among CHN and other hospitals in the area. With the high success 
rate of patients completing OPAT therapy, prescribers can feel confident utilizing OPAT 
in the future when appropriate for infections requiring longer durations of IV antibiotics. 
As OPAT gains popularity among healthcare providers, the demographics of additional 
programs could help to establish improved protocols and best practices.  
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Figure 1.  
 
  
284 patients 
evaluated
58 
excluded
No OPAT initiated (n=5)
Lost to follow-up (n=20)
Not initiated at CHN (n=3)
Unable to locate EMR (n=5)
Pregnant (n=1)
< 18 years old (n=1)
> 89 years old (n=3)
OPAT outside of study period (n=20)
226 included
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Table 1. Patient Demographics 
Sex, n (%)  
Male 125 (55.3) 
Female 101 (44.7) 
Race/Ethnicity, n (%)  
White 180 (79.6) 
African American 44 (19.5) 
Other 1 (0.4) 
Unknown 1 (0.4) 
Asian 0 
Hispanic 0 
Age, n (%)  
20-30 11 (4.9) 
30-40 22 (9.7) 
40-50 20 (8.8) 
50-64 90 (39.8) 
65-79 78 (34.5) 
80-89 5 (2.2) 
Insurance Coverage, n (%)  
Medicaid 44 (19.4) 
Medicare 119 (52.6) 
Commercial 61 (27.0) 
Other 1 (0.4) 
None 1 (0.4) 
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Table 2. Infection Types  
Other, n (%) 80 (35.4) 
Osteomyelitis, n (%) 65 (28.7) 
Endocarditis, n (%) 15 (6.6) 
Skin and Soft Tissue Infections, n (%) 15 (6.6) 
Bacteremia, n (%)  13 (5.8) 
Urinary Tract Infection/Pyelonephritis, n (%) 10 (4.4) 
Pneumonia, n (%) 9 (3.9) 
Intraabdominal, n (%) 5 (2.2) 
Meningitis, n (%) 4 (1.7) 
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Table 3. Source Organisms 
Other, n (%) 66 (29.2) 
Methicillin sensitive Staphylococcus aureus (MSSA), n (%) 59 (26.1) 
Culture Negative, n (%) 36 (15.9) 
Methicillin resistant Staphylococcus aureus (MRSA), n (%) 31 (13.7) 
Group B Streptococcus, n (%) 17 (7.5) 
Pseudomonas spp., n (%) 16 (7.1) 
Enterococcus spp., n (%) 14 (6.2) 
Escherichia Coli, n (%) 13 (5.7) 
Streptococcus pneumoniae, n (%) 2 (0.8) 
Atypical organisms, n (%) 0 (0) 
Anaerobic organisms, n (%) 0 (0) 
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Table 4. Antibiotics 
Vancomycin, n (%) 67 (29.6) 
3rd Generation Cephalosporin, n (%) 60 (26.5) 
1st Generation Cephalosporin, n (%) 52 (23.0) 
Other, n (%) 38 (16.8) 
Carbapenem, n (%) 35 (15.5) 
Nafcillin, n (%) 4 (1.7) 
4th Generation Cephalosporin, n (%) 2 (0.8) 
2nd Generation Cephalosporin, n (%) 0 (0) 
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Table 5. Pharmacist Interventions 
Level Evaluation with dose adjustment, n (%) 56 (24.7) 
Lab Follow-up, n (%) 46 (20.4) 
Level Evaluation without dose adjustment, n (%) 13 (5.7) 
Antibiotic Change, n (%) 12 (5.3) 
Dose Change, n (%) 5 (2.2) 
Frequency Change, n (%) 3 (1.3) 
Other, n (%) 3 (1.3) 
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